Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 304.00
Bid: 301.00
Ask: 304.00
Change: 14.00 (4.83%)
Spread: 3.00 (0.997%)
Open: 310.00
High: 314.00
Low: 304.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chi-Med to Attend Upcoming Investor Conferences

11 May 2020 07:00

RNS Number : 3486M
Hutchison China Meditech Limited
11 May 2020
 

Press Release

Chi-Med to Attend Upcoming Investor Conferences

London: Friday, May 11, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time (EDT).

 

The discussion will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

 

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference on May 14, as well as during the following other conferences:

 

· Citi Virtual Pan-Asia Regional Investor Conference from Tuesday to Thursday, May 19 to 21, 2020;

 

· Jefferies Virtual Global Healthcare Conference from Tuesday to Thursday, June 2 to 4, 2020; and

 

· Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Thursday, June 9 to 11, 2020.

 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

 

CONTACTS

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com

Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMZGGKRRZGGZG
Date   Source Headline
6th Jun 20197:00 amRNSDisclosure Update
31st May 20194:40 pmRNSSecond Price Monitoring Extn
31st May 20194:35 pmRNSPrice Monitoring Extension
29th May 201912:06 pmRNSResults of Extraordinary General Meeting
22nd May 201911:03 amRNSGrant of Share Options under Share Option Scheme
3rd May 20197:00 amRNSNotice of EGM & Shareholder Circular
24th Apr 20191:54 pmRNSResults of AGM
15th Apr 20197:30 amRNSDisclosure Update
15th Apr 20197:00 amRNSHK Listing Application - Proposed Global Offering
29th Mar 20197:00 amRNSStart of Phase IIb/III Surufatinib Trial in China
28th Mar 20197:30 amRNSSavolitinib Lung Cancer Presentations at AACR
25th Mar 20197:00 amRNSVesting of awards under Long Term Incentive Plan
21st Mar 20197:00 amRNSChi-Med 2018 Annual Report and Notice of AGM
11th Mar 201912:54 pmRNSPublication of Form 20-F
11th Mar 20197:00 amRNS2018 FY Results and Key Clinical Programs Update
12th Feb 20197:00 amRNSSavolitinib PRCC Data to be presented at ASCO GU
8th Feb 20197:00 amRNSChi-Med to Announce 2018 Final Results
7th Jan 20197:00 amRNSChi-Med Presents at JPM Healthcare Conference
31st Dec 20187:00 amRNSBlocklisting Six Monthly Return
31st Dec 20187:00 amRNSTotal Voting Rights
24th Dec 201812:41 pmRNSSecond Price Monitoring Extn
24th Dec 201812:36 pmRNSPrice Monitoring Extension
20th Dec 20187:13 amRNSChi-Med announce Savolitinib program update
20th Dec 20187:00 amRNSAmendment to Lilly Agreement on Fruquintinib
14th Dec 20187:21 amRNSTR-1: Form for notification of major holdings
30th Nov 20187:00 amRNSTotal Voting Rights
29th Nov 20188:00 amRNSChi-Med Enters into Multiple Collaborations
26th Nov 20187:00 amRNSFirst Commercial Launch of Fruquintinib Capsules
16th Nov 20187:00 amRNSPhase III FALUCA Trial Results for Fruquintinib
31st Oct 20187:00 amRNSTotal Voting Rights
22nd Oct 201810:05 amRNSGrant of Share Options under Share Option Scheme
18th Oct 20187:00 amRNSChi-Med Initiates a Ph I Trial of HMPL-523 for AML
5th Oct 20187:00 amRNSAppointment of HSBC Bank plc as Broker in London
5th Sep 20187:00 amRNSFruquintinib Approved for CRC in China
31st Aug 20187:00 amRNSTotal Voting Rights
7th Aug 201810:00 amRNSGrant of Share Options under Share Option Scheme
27th Jul 20187:00 amRNS2018 Interim Results and Clinical Programs Update
23rd Jul 20187:00 amRNSStart of Sulfatinib US Phase Ib/II PoC trial
29th Jun 20187:02 amRNSTotal Voting Rights
29th Jun 20187:01 amRNSBlocklisting Six Monthly Return
29th Jun 20187:00 amRNSChi-Med to Announce Half-Year Financial Results
7th Jun 201810:00 amRNSGrant of Share Options under Share Option Scheme
4th Jun 20189:41 amRNSFurther Fruquintinib FRESCO Trial Data - ASCO 2018
31st May 20187:00 amRNSTotal Voting Rights
30th Apr 20187:00 amRNSTotal Voting Rights
27th Apr 20181:52 pmRNSResults of Annual General Meeting
23rd Apr 20181:10 pmRNSGrant of Share Options under Share Option Scheme
23rd Apr 20181:05 pmRNSBlock Admission
29th Mar 20187:00 amRNSTotal Voting Rights
28th Mar 20187:00 amRNSVesting of awards under Long Term Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.